Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 866 shares of the biopharmaceutical company’s stock after selling 79 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Regeneron Pharmaceuticals were worth $617,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Swedbank AB raised its holdings in shares of Regeneron Pharmaceuticals by 19.5% during the fourth quarter. Swedbank AB now owns 178,491 shares of the biopharmaceutical company’s stock valued at $127,144,000 after acquiring an additional 29,128 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its stake in Regeneron Pharmaceuticals by 0.9% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 129,308 shares of the biopharmaceutical company’s stock valued at $92,110,000 after purchasing an additional 1,130 shares during the last quarter. R Squared Ltd purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $435,000. SteelPeak Wealth LLC boosted its stake in Regeneron Pharmaceuticals by 154.8% during the 4th quarter. SteelPeak Wealth LLC now owns 2,823 shares of the biopharmaceutical company’s stock worth $2,011,000 after purchasing an additional 1,715 shares during the last quarter. Finally, Tamar Securities LLC raised its position in shares of Regeneron Pharmaceuticals by 31.7% in the fourth quarter. Tamar Securities LLC now owns 20,401 shares of the biopharmaceutical company’s stock valued at $14,532,000 after buying an additional 4,909 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6 %

REGN opened at $683.08 on Friday. The business has a fifty day moving average price of $723.36 and a 200 day moving average price of $928.61. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 12 month low of $666.25 and a 12 month high of $1,211.20. The stock has a market capitalization of $75.06 billion, a price-to-earnings ratio of 16.90, a PEG ratio of 1.59 and a beta of 0.10.

Analysts Set New Price Targets

Several analysts recently issued reports on REGN shares. Sanford C. Bernstein dropped their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Finally, Bank of America reissued an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.